Sandoz Says High Court Should Review BPCIA To Avoid Delay For Patient Access To Biosimilar
WASHINGTON, D.C. — Sandoz Inc. argues in a brief filed May 31 that the U.S. Supreme Court should consider reviewing the Biologics Price Competition and Innovation Act (BPCIA) because until it...To view the full article, register now.
Already a subscriber? Click here to view full article